InsidersTradesSigma
Follow the Vir Biotechnology, Inc. stock price and the full insider trade history of the company, a listed issuer based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Vir Biotechnology, Inc. has logged 340 public disclosures. Market capitalisation: €1.7bn. The latest transaction was disclosed on 25 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: SVF Endurance (Cayman) Ltd. Every trade is openly available.
340
Insider Decl.
n/a
Thresholds
€172,916
4 ops.
Buy Volume
€88m
145 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Vir Biotechnology, Inc. Strong Buy (bullish), based on 9 analysts. Average price target: US$21.00.
47Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 22,617 of 29,062 companies
32.3
score / 100
Value9
Quality55
FCF yld-22%
Earn yld-24%
EV/EBITDA·
ROE-26%
Gross mgn100%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 25 August 2026
Declarations340 total
23,148 shares@ US$10.48CommonSEC144:0001959173-26-006425
14,352 shares@ US$9.90270.0085% mcap32.3% of flowCommonSEC144:0001959173-26-006413
25,000 shares@ US$9.81190.015% mcap82.1% of flowCommonSEC144:0001959173-26-006329
8,000 shares0Common StockSEC:0001628280-26-056108:1
8,000 shares0Common StockSEC:0001628280-26-056108:0
16,000 shares@ US$10.32120.0100% mcap33.1% of flowCommonSEC144:0001959173-26-004947
8,000 sharesCommon StockSEC:0001628280-26-042326:0
8,000 sharesCommon StockSEC:0001628280-26-042326:1
8,000 shares0Common StockSEC:0001628280-26-038961:0
8,000 shares0Common StockSEC:0001628280-26-038962:0
22,000 shares@ US$10.04660.014% mcap2.1% of flowCommon StockSEC:0001628280-26-029640:0
233,532 shares0Common StockSEC:0001628280-26-029041:1
233,532 shares0Common StockSEC:0001628280-26-029041:0
72,559 shares@ US$9.15635.1% of flowCommon StockSEC:0001628280-26-024098:0
22,000 shares@ US$9.07350.013% mcap1.9% of flowCommon StockSEC:0001628280-26-022971:0
7,711 shares@ US$9.1281.6% of flowCommon StockSEC:0001628280-26-020823:0
2,500 shares0Common StockSEC:0001628280-26-020480:0
21,800 shares@ US$9.50391.7% of flowCommon StockSEC:0001628280-26-013630:0
1,616 shares@ US$9.53260.0010% mcap50.0% of flowCommon StockSEC:0001628280-26-012394:0
3,117 shares@ US$9.53260.0018% mcap50.0% of flowCommon StockSEC:0001628280-26-012393:0
42,377 shares@ US$1.4850.5% of flowCommon StockSEC:0001628280-26-012397:0
1,430 shares@ US$9.532612.0% of flowCommon StockSEC:0001628280-26-012396:0
1,634 shares@ US$9.532628.9% of flowCommon StockSEC:0001628280-26-012395:0
14,762 shares@ US$9.53266.8% of flowCommon StockSEC:0001628280-26-012390:0
25,000 shares0Common StockSEC:0001628280-26-011331:0
25 of 340 declarations
关于 Vir Biotechnology, Inc.
Vir Biotechnology, Inc. 是一家总部位于美国的生物制药公司，在美国纳斯达克市场上市，专注于发现和开发严重传染病的疗法，近期已扩展到选定的肿瘤学应用。该公司成立于 2016 年，总部位于加利福尼亚州旧金山，其建立基于技术驱动的方法，结合抗体、免疫学和蛋白质掩蔽平台，以产生差异化的治疗候选药物。（[stockanalysis.com](https://stockanalysis.com/stocks/vir/company/?utm_source=openai)) 从历史角度看，Vir Biotechnology 最初围绕高未满足需求的病毒性疾病确立了其身份。其产品组合长期以来包括乙型肝炎、丁型肝炎、艾滋病毒、流感和 COVID-19 等项目，涵盖从临床前研究到更高级的临床阶段。在其近期沟通中，该公司已表明采取更具选择性和以伙伴关系为导向的战略，同时对其多个项目（包括乙型肝炎、流感、COVID-19 和 HPV）的对外许可讨论保持开放。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1706431/000162828024006852/vir-20231231.htm?utm_source=openai)) 在竞争方面，Vir 在一个竞争激烈的领域中运营，该领域有大型制药公司和众多专注于免疫学和传染病的生物技术同行。其竞争优势集中在其平台的科学质量、转化研究的深度以及与主要行业参与者建立伙伴关系的能力。该公司已利用许可和合作协议来支持资产货币化，同时减轻独立资助整个产品线的负担。（[investors.vir.bio](https://investors.vir.bio/news/news-details/2025/Vir-Biotechnology-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-EGFR-Targeting-PRO-XTEN-Dual-Masked-T-Cell-Engager-VIR-5525-for-the-Treatment-of-Solid-Tumors/default.aspx?utm_source=openai)) 在最近最值得关注的进展中，Vir Biotechnology 于 2025 年宣布了 VIR-5525 的首次人体给药，这是一种用于实体瘤的掩蔽 EGFR 靶向 T 细胞衔接器，突显了其在传染病之外的多元化发展。该公司还在 2026 年发布了 2025 年全年业绩，强调了积极的资本管理和持续的临床进展。对于法语投资者而言，关键问题仍然是 Vir 能否在一个高度选择性的纳斯达克生物技术环境中，将一个科学上有前景的平台转化为持久的临床价值，并最终实现商业价值创造。（[investors.vir.bio](https://investors.vir.bio/news/news-details/2025/Vir-Biotechnology-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-EGFR-Targeting-PRO-XTEN-Dual-Masked-T-Cell-Engager-VIR-5525-for-the-Treatment-of-Solid-Tumors/default.aspx?utm_source=openai))
